Iritero 40 mg Injection
$7,12
$4,13
Iritero 40 mg Injection is a potent topoisomerase inhibitor designed for the effective treatment of advanced colorectal cancer. This medication can be administered alone or in conjunction with 5-fluorouracil and folinic acid, particularly for patients who have not undergone prior chemotherapy for advanced disease. Iritero plays a crucial role in the first-line therapy for individuals suffering from metastatic carcinoma of the colon or rectum, disrupting cancer cell replication and ultimately impeding tumor growth. It is important for patients to be aware of potential side effects, including gastrointestinal issues and hematologic toxicity, which may require monitoring during treatment. As with any chemotherapy regimen, discussions with healthcare providers regarding benefits and risks are essential for optimal outcomes. Patients should also inform their doctors about any existing health conditions or medications to avoid harmful interactions. By understanding how Iritero works and adhering to medical guidance, patients can take an active role in their cancer treatment journey. Overall, Iritero 40 mg Injection represents a significant advancement in the fight against colorectal cancer, offering hope and improved quality of life to those affected by this challenging disease.
數量
Active Pharmaceutical Ingredient
Uses
• Iritero 40 mg injection is primarily used in the treatment of advanced colorectal cancer. It works as part of a combination chemotherapy regimen, targeting cancer cells to inhibit their growth. This medication is typically administered in a clinical setting by trained healthcare professionals. The treatment plan is tailored to each patient's specific cancer type and stage.
• In addition to colorectal cancer, Iritero 40 mg injection may also be utilized for certain types of gastrointestinal tumors. Its effectiveness in slowing down tumor progression makes it a valuable option in managing these cancers. The injection is given intravenously, ensuring rapid delivery of the active ingredient. This method of administration allows for better control of the treatment process.
• Iritero 40 mg injection is often part of a multi-drug chemotherapy approach, which can enhance overall treatment efficacy. By combining Iritero with other agents, healthcare providers aim to maximize the therapeutic impact on cancer cells. The decision to include Iritero in the regimen is based on individual patient assessments and clinical guidelines. This collaborative treatment strategy is essential for optimizing outcomes.
• Healthcare professionals monitor patients closely during the administration of Iritero 40 mg injection. This allows for timely adjustments to the treatment plan, ensuring that it remains effective and aligned with the patient's needs. The injection is typically given in a hospital or specialized clinic, where patients receive comprehensive care. This supportive environment is crucial for managing the complexities of cancer treatment.
Benefits
Treatment of colon and rectum cancer: Cancer of the colon and rectum, also known as colorectal cancer (CRC) or bowel cancer, is the development of cancer from two parts of the large intestine, namely, the colon or rectum. In this type of cancer, the person may notice symptoms such as blood in the stool, a change in bowel movements, weight loss, and fatigue. Iritero 40 mg Injection treats and also lowers the risk of developing further cancerous growths (polyps) and bowel cancer. It kills or stops the growth of cancer cells and also prevents the multiplication of cancer cells. It is an effective, yet very toxic medicine and you should discuss the risks and benefits with your doctor. Avoid drinking alcohol or smoking while having this treatment and drink plenty of water to stay hydrated.
Side Effects
Like all medications, Iritero Anti-cancer Injection can cause side effects but do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about them.
Most Common Side Effects
• Nausea
• Vomiting
• Constipation
• Fever
• Infection
• Pain
Common Side Effects
• Diarrhea
• Kidney Impairment
• Lung Problems
• Low blood count
How To Use
Irinotecan 40 mg is administered by a qualified doctor or nurse at a hospital or clinical setting. It is given intravenously and is usually given as part of a combination chemotherapy regimen. The specific treatment plan and dosage will depend on the type and stage of the cancer being treated, as well as other individual factors determined by the healthcare provider.
Safety Advice
• Alcohol: It is generally not recommended to drink alcohol while taking Iritero 40 mg Injection. It may increase the risk of liver damage. it is best to avoid alcohol or limit your alcohol consumption while taking any medication.
• Kidney: Iritero 40 mg Injection should be used with caution in patients with kidney disease. It is important that patients with kidney disease closely monitor kidney function while taking Iritero 40 mg Injection and report any unusual symptoms or changes in kidney function to their doctor. Iritero 40 mg Injection is not recommended for use in patients on dialysis.
• Breastfeeding: The available data are limited but suggest that Iritero 40 mg Injection and its metabolite are excreted in human milk. Consequently, because of the potential for adverse reactions in nursing infants, breastfeeding should be discontinued for the duration of Iritero 40mg/2ml Vial therapy.
• Liver: Irinotecan 40 mg should be used with caution in patients with liver disease. It is important that patients with liver disease closely monitor liver function while taking Iritero Anti-cancer Injection and report any unusual symptoms or changes in liver function to their doctor. The dose of Iritero 40 mg Injection may need to be adjusted in patients with liver disease.
• Pregnancy: There are limited data on the use of irinotecan in pregnant women. Irinotecan 40 mg has been shown to be embryotoxic and teratogenic in animals. Therefore, based on results from animal studies and the mechanism of action of Iritero 40 mg Injection, Iritero 40 mg Injection should not be used during pregnancy unless clearly necessary. Women of childbearing potential should not be started on Irinotecan Injection 2 ml until pregnancy is excluded. Pregnancy should be avoided if either partner is receiving Iritero 40 mg Injection.
• Driving: Iritero 40 mg Injection has a moderate influence on the ability to drive and use machines. Patients should be warned about the potential for dizziness or visual disturbances, which may occur within 24 hours following the administration of Irinotecan Injection 2 ml, and advised not to drive or operate machinery if these symptoms occur.